Investing.com - Day One Biopharmaceuticals (NASDAQ: DAWN) reported first quarter EPS of $-0.59, in line with the analyst estimate of $-0.59. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Day One Biopharmaceuticals's stock price closed at $12.40. It is down -42.41% in the last 3 months and up 57.87% in the last 12 months.
Day One Biopharmaceuticals saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Day One Biopharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Day One Biopharmaceuticals's Financial Health score is "weak performance".
Check out Day One Biopharmaceuticals's recent earnings performance, and Day One Biopharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar